Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Letong Cai, Yuchen Li, Jiaxiong Tan, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 119

Showing 1-25 of 119 citing articles:

Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Qiang Liu, Yujing Guan, Shenglong Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Tianye Li, Mengke Niu, Jianwei Zhou, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 14
The TGF-β Family in Glioblastoma
Irene Golán‐Cancela, Laia Caja
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1067-1067
Open Access | Times Cited: 13
Regulatory T cells in immune checkpoint blockade antitumor therapy
An Zhang, Tao Fan, Yixiao Liu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients
Abdullah Al-Danakh, Mohammed Safi, Yuli Jian, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Stephanie Pitts, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment
Pankaj Kumar Garg, Siddhika Pareek, Prakash Kulkarni, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6537-6537
Open Access | Times Cited: 8
Unleashing the Power of immune Checkpoints: A new strategy for enhancing Treg cells depletion to boost antitumor immunity
Guoxin Li, Siqi Li, Yi Jiang, et al.
International Immunopharmacology (2025) Vol. 147, pp. 113952-113952
Open Access | Times Cited: 1
New insight in immunotherapy and combine therapy in colorectal cancer
Kai Ji, Hang Jia, Zixuan Liu, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 1
Immunosenescence promotes cancer development: from mechanisms to treatment strategies
Leihan Wang, Tang Dong
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Novel immune checkpoint targets: A promising therapy for cancer treatments
Mohsina Patwekar, Nouroz Sehar, Faheem Patwekar, et al.
International Immunopharmacology (2023) Vol. 126, pp. 111186-111186
Closed Access | Times Cited: 20
Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses
Jiabao Tian, Camelia Quek
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4243-4243
Open Access | Times Cited: 7
Determinants of resistance and response to melanoma therapy
Bailey M. Robertson, Mitchell E. Fane, Ashani T. Weeraratna, et al.
Nature Cancer (2024) Vol. 5, Iss. 7, pp. 964-982
Closed Access | Times Cited: 7
Innate Immune Cells in Tumour Microenvironment: A New Frontier in Cancer Immunotherapy
Changhui Li, Xinyu Yu, Xinyan Han, et al.
iScience (2024) Vol. 27, Iss. 9, pp. 110750-110750
Open Access | Times Cited: 7
Engineered biological nanoparticles as nanotherapeutics for tumor immunomodulation
Juwita N. Rahmat, Jiayi Liu, Taili Chen, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 11, pp. 5862-5903
Open Access | Times Cited: 6
Immune checkpoint blockade in hematological malignancies: current state and future potential
Prateek Pophali, Juan Carlos Varela, Jacalyn Rosenblatt
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations
Alexander K. Tsai, Sana Kagalwalla, Jenna Langer, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 1-2, pp. 51-62
Closed Access | Times Cited: 5
Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment
Yulei Mu, Zhen Zhang, Huiqun Zhou, et al.
Biomaterials Science (2024) Vol. 12, Iss. 16, pp. 4045-4064
Closed Access | Times Cited: 5
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Jing Wei, Wenke Li, Pengfei Zhang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
A therapeutic regimen using neoantigen-specific TCR-T cells for HLA-A*2402-positive solid tumors
Yuncheng Bei, Ying-Wen Huang, Nandie Wu, et al.
EMBO Molecular Medicine (2025)
Open Access
Checkpoint receptors in circulating γδ T cells can discern the outcome of cancer immunotherapy
Elisa Catafal Tardos, Lola Dachicourt, María Virginia Baglioni, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Immunotherapy in Recurrent Ovarian Cancer
Keyao Chen, Jingjing Wang, Meng Yang, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 168-168
Open Access
New insights into the ferroptosis and immune infiltration in endometriosis: a bioinformatics-based analysis
Lusha Liu, Feifei Han, Naiyi Du, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Reversing NK cell exhaustion: a novel strategy combining immune checkpoint blockade with drug sensitivity enhancement in the treatment of hepatocellular carcinoma
Yuxiang Huang, Hengjian Liao, Jiefu Luo, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020-2024)
Qiaohong Geng, Juanjuan Xu, Cheng Du, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Page 1 - Next Page

Scroll to top